Investors

We have strong financial and industrial shareholders.

Annual financial statements, quarterly reports and presentations.

Please contact our IR Contacts for any queries.

Start of inclusion of additional group of 10 patients in the ongoing US based phase I trial in malignant melanoma
(1 October 2019)